Inhibiting PHGDH expression and disrupting the interactions between PHGDH and eIF4A1/eIF4E provide new prospects for anti-tumor therapeutics designs, which are meaningful for improving the pancreatic cancer treatment effect and prolonging the overall survival of clinical patients. This evidence concerns the gene EIF4E and familial pancreatic carcinoma.